Liminal BioSciences Inc

Liminal BioSciences — Investor Presentation (June 2023)

33 slides from Liminal BioSciences's investor presentation, Jun 2, 2023

  1. Slide 1: GPCR Drug Development Seeking Co-Development Partners

    GPCR DRUG DEVELOPMENT INVOLVING CHALLENGING, HIGH-VALUE TARGETS SEEKING GLOBAL & REGIONAL CO-DEVELOPMENT PARTNERS TO ACCELERATE THE PATH TO MARKET JUNE 2023 NASDAQ: LMNL

  2. Slide 2: Forward-looking information

    Forward–looking information includes statements concerning, among other things: advancement of Liminal Biosciences' candidates or development programs, including the timing and outcome of the potential development of the Company's R&D programs such as the development of LMNL6511, LMNL6326 and our GP

  3. Slide 3: Why partner with Liminal?

    Why partner with liminal? Novel therapeutic candidates designed for high-value GPCR targets Innovation & Leadership in the sought-after field of G Protein-Coupled Receptors (GPCRs) Developing drug candidates for difficult targets of high value (‘undruggable’) Validated target engagement & activity;

  4. Slide 4: GPCR Molecular Target Opportunities

    GPCR MOLECULAR TARGET OPPORTUNITIES ~400 GPCR targets active in diseases2 GPCRs ARE COMPELLING TARGETS FOR THERAPEUTIC DEVELOPMENT ~34% of FDA approvals target GPCRs1 Sources: 1 “Unexplored opportunities in the druggable human genome”, Nature Reviews, 2016 ; 2 “Trends in GPCR in Drug Discovery – new

  5. Slide 5: GPCR pipeline focuses on chronic disease, high-value markets

    Lmnl’s gpcr pipeline focuses on Chronic Disease, high-value markets 1Centers of Disease Control and Prevention, March 2020 (NHANES, 2021); 2BioSpace, Inc. (syndicated report), July 2021; 3Younossi, Z, et al. Journ of Hepatol 2019;71:793-801; 4Global Industry Analysts, Inc. (syndicated report), Octob

  6. Slide 6: GPCR Drug Discovery pipeline features novel targets

    GPCR Drug Discovery pipeline features novel targets Small molecule pipeline targeting metabolic, inflammatory and fibrotic diseases. Global Rights Program Potential Indications Preclinical Clinical Key Milestones Discovery Lead Optimisation CTA-enabling Phase 1 Phase 2 Phase 3 GPR84 Antagonist IBD N

  7. Slide 7: GPR84: broad therapeutic area potential

    GPR84: broad therapeutic area potential, with multi-tissue involvement GPR84 is a pro-inflammatory G protein-coupled receptor (GPCR) mainly expressed in neutrophils, monocytes, macrophages and other innate immune cells in the peripheral system, and microglial cells in the nervous central system. GPR

  8. Slide 8: LMNL6511 GPR84 Antagonist Program

    LMNL6511 GPR84 Antagonist Program

  9. Slide 9: GPR84: A pivotal role in inflammation and fibrosis

    GPR84: A PIVOTAL ROLE IN INFLAMMATION AND FIBROSIS Primarily expressed in immune cells, such as neutrophils, monocytes, and macrophages Abundant in multiple organ systems: heart, lung, kidney, liver, GI tract, CNS and bone marrow.1 WHAT IS THE GPR84 RECEPTOR? GPR84 antagonism is anticipated to addre

  10. Slide 10: GPR84 antagonists: Open Development Landscape for LMNL6511

    GPR84 antagonists: Open Development Landscape for LMNL6511 Few Competitive Programs; one clinical program for Neuropathic Pain Labéguère et al., 2020; Mahindra et al., 2022; Chen et al., 2022 GLPG1205 - halted (and related dihydropyrimidino isoquinolinone compounds) BGT-004 (and related phosphodiest

  11. Slide 11: LMNL6511: Candidate Selection & Development Rationale

    LMNL6511: Candidate Selection & Development Rationale Liminal’s potent and selective GPR84 antagonist has IP and patent filings for the treatment of inflammatory/fibrotic/metabolic diseases, including NAFLD/NASH and IBD/UC. > 1700 compounds synthesized & tested; LMNL6511 was screened for greater pot

  12. Slide 12: PK/potency of GLPG1205 vs potency of LMNL6511

    PK/potency of GLPG1205 vs potency of LMNL6511 Results from GLPG1205 Phase 1 study (Timmis et al., 2021; adapted from Figure 2) vs in vitro potency IC50 and IC90 were established internally using the human GPR84 trafficking to early endosomes assay Taking into consideration the higher potency observe

  13. Slide 13: GLPG1205 Reported Clinical Safety and Tolerability

    GLPG1205 Reported Clinical Safety and Tolerability Phase 1 study (Clinicaltrials.gov number NCT01887106; Timmis et al., 2021) Randomized, double-blind, placebo-controlled study of GLPG1205 (part 1: SAD GLPG1205 10 to 800 mg; part 2: MAD GLPG1205 50, 100, or 200 mg once daily for 14 days). Reduced to

  14. Slide 14: Insights from LMNL NASH liver disease in-vivo studies

    Results suggests that treatment with a small molecule GPR84 antagonist for 6 weeks could improve liver fibrosis and health in a model of diet-induced liver disease (high fat diet). Treated mice have shown: reduced ALT concentration in the serum reduced liver hypertrophy reduced steatosis as well as

  15. Slide 15: Key take-aways from LMNL IBD in vivo studies

    LMNL6511 was evaluated in the indomethacin-induced inflammatory bowel disease rat model. Results showed a reduction in the number of indomethacin-induced lesions and macroscopic disease grade in rats dosed with LMNL6511. We also showed an improvement in the albuminemia (indicating reduction in gut b

  16. Slide 16: GPCR partnerships

    GPCR partnerships COMPANIES INDICATIONS STAGE OF ASSETS AT TIME OF PARTNERSHIP COLLABORATION GOALS Tempero Bio & Sosei Heptares Neurological & Psychiatric Disorders Phase 1 Develop potent, orally available mGluR5 negative allosteric modulators. Lead compound TMP-301 (HTL0014242) was designed by Sose

  17. Slide 17: Liminal's partnering approach & timeline

    LIMINAL’S PARTNERING APPROACH & TIMELINE Opportunity to secure an option & license agreement for a novel, Phase 1 asset with potential to address unmet need in metabolic, inflammatory & fibrotic-driven diseases; >10% CAGR by 20301,2 Unencumbered competitive landscape: few groups working on GPR84, ma

  18. Slide 18: LMNL6326 OXER1 Antagonist Program

    LMNL6326 OXER1 Antagonist Program

  19. Slide 19: OXER1 Potential To Treat Eosinophilic-Driven Disease

    OXER1 Potential To Treat Eosinophilic-Driven Disease Gastrointestinal Diseases Respiratory Diseases Other Diseases Skin Diseases Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. Both eosinoph

  20. Slide 20: OXER1 role in asthma

    OXER1 ROLE IN Disease is Driven By Eosinophilic Immune Dysfunction Asthma is a heterogeneous disease; there are multiple clinical sub-types The two primary asthma phenotypes, Type 2 high and Type 2 low, are defined by eosinophilic and neutrophilic pattern of inflammation, respectively The Type 2 hig

  21. Slide 21: Eosinophilic and severe asthma markets

    EOSINOPHILIC AND SEVERE ASTHMA MARKETS MAY PROVIDE MORE POTENTIAL COMMERCIAL OPPORTUNITY FOR EFFECTIVE, TARGETED THERAPIES $1.3B 2021 SALES est. $2.2B in peak sales (’27)3 9 Approved Products: 5 Topical, 2 Oral and 2 injection2 $1.6B 2021 SALES est. $2.6B in peak sales (‘27)3 Market expected to reac

  22. Slide 22: OXER1 role in atopic dermatitis

    OXER1 ROLE IN Disease is Driven By Eosinophilic Immune Dysfunction The immune response observed during the course of Atopic Dermatitis (AD) is characterized by a biphasic inflammation. A Th2-biased immune response (IL-4, IL-13, TSLP and eosinophils) is predominant in the initial and acute phase of A

  23. Slide 23: No other OXER-1 antagonists in development in atopic dermatitis market

    NO OTHER OXER-1 ANTAGONISTS IN DEVELOPMENT IN LARGE AND GROWING GLOBAL ATOPIC DERMATITIS MARKET 1 Future Market Insights, Atopic Dermatitis Market Forecast 2021-2029, 2 FDA Centerwatch Approved Drug listing in Atopic Dermatitis, 3Company Website’s, Dupixent indicated in eosinophilic esophagitis, eos

  24. Slide 24: OXER1 antagonist Candidate Selection & Development Rationale

    OXER1 antagonist Candidate Selection & Development Rationale Liminal’s potent and selective OXER1 antagonist has IP and patent filings for the treatment of inflammatory, allergic, and proliferative diseases involving eosinophils and neutrophils. An OXER1 antagonist was found to have positive effects

  25. Slide 25: OXER1 antagonist with potential numerous clinical applications

    1Dagmar, et al. Current reviews of allergy and clinical immunology. Eosinophilic disorders. 2007. American Academy of Allergy, Asthma & Immunology doi:10.1016/j.jaci.2007.02.010 TARGET Receptor for inflammatory mediator 5-oxo-ETE RATIONALE Blocks potent proinflammatory mediator on eosinophils1 LIMIN

  26. Slide 26: OXER1: Role in tissue repair and inflammation

    OXER1: ROLE IN TISSUE REPAIR AND INFLAMMATION OXER1 is a GPCR receptor which is mainly expressed in inflammatory cells. OXER1 is highly selective for 5-oxo-ETE, one of the most powerful chemo-attractants and activators of eosinophils. WHAT IS THE OXER1 RECEPTOR? Eosinophils are involved in acute and

  27. Slide 27: GPR40 Agonist Program

    Liminal BioSciences P GPR40 AGONIST PROGRAM © 2023 Liminal BioSciences Inc.

  28. Slide 28: GPR40: Role in metabolic syndrome and glucose management

    GPR40: ROLE IN METABOLIC SYNDROME AND GLUCOSE MANAGEMENT GPR40, also known as FFA1 or FFAR1, is a GPCR highly expressed in pancreatic β-cells and responds to medium and long chain unsaturated fatty acids, resulting in increased insulin secretion only in the presence of elevated glucose levels. WHAT

  29. Slide 29: GPR40/FFAR1 Agonists: An Emerging Class of Compounds for T2D

    GPR40/FFAR1 Agonists: An Emerging Class OF COMPOUNDS for T2D GPR40 is a validated target for the treatment of Type 2 Diabetes Strong clinical evidence that GPR40 agonists can improve glucose control, without the risk of hypoglycemia. Liver toxicity led to the discontinuation of the most advanced cli

  30. Slide 30: Development Activities & Leadership

    30 © 2023 Liminal BioSciences Inc. DEVELOPMENT ACTIVITIES & LEADERSHIP

  31. Slide 31: Data driven execution and delivery

    DATA DRIVEN EXECUTION AND DELIVERY H1 2023 On-going In-vivo experiments expected to allow narrow down a lead clinical indication 2023 Ongoing CTA-enabling studies for first-in-human clinical trial H2 2023 Expect to file CTA for first-in-human Phase 1 clinical trial H2 2023 Expect to Commence first-i

  32. Slide 32: Management team with track record of success

    MANAGEMENT TEAM WITH TRACK RECORD OF SUCCESS BRUCE PRITCHARD Chief Executive Officer NICOLE RUSAW Chief Financial Officer Marie Iskra General Counsel & Secretary DR. GARY BRIDGER Board Member and Interim Chief Scientific Officer Patrick Sartore President LMNL is led by a strong, experienced team wit

  33. Slide 33: Board of directors

    BOARD of directors Alek Krstajic Director Neil A. Klompas Chair Audit, Risk & Finance Committee Simon G. Best (OBE) Chair, Human Resources & Corporate Governance Committee Timothy S. Wach Director DR. GARY BRIDGER Director Eugene Siklos Director As former Chief Executive Officer of Wind Mobile, Alek

Liminal BioSciences — Investor Presentation (June 2023) on 6ix